• Explore /
  • Poster
  • / A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Abstract Poster

Authors

null

Richard S. Finn

Geffen School of Medicine at UCLA, Los Angeles, CA

Richard S. Finn , Ann-Lii Cheng , Kenji Ikeda , Masatoshi Kudo , Toshiyuki Tamai , Corina E. Dutcus , Steven Younger , Kwang-Hyub Han , Shukui Qin , Eric Raymond

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01761266

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4153)

DOI

10.1200/jco.2014.32.15_suppl.tps4153

Abstract #

TPS4153

Poster Bd #

235B

Abstract Disclosures

Similar Posters

First Author: Ari David Baron

First Author: Claudia A.M. Fulgenzi

First Author: David Trueman

First Author: Jasmine Huynh